(Q39412753)

English

Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity

scientific article published on November 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity (English)

1 reference

Europe PubMed Central

11 September 2017

arterial hypertension

0 references

8

object named as

Seeger W

1 reference

Europe PubMed Central

11 September 2017

Norbert Weissmann

0 references

author name string

Schermuly RT

1

1 reference

Europe PubMed Central

11 September 2017

Krupnik E

2

1 reference

Europe PubMed Central

11 September 2017

Tenor H

3

1 reference

Europe PubMed Central

11 September 2017

Schudt C

4

1 reference

Europe PubMed Central

11 September 2017

Weissmann N

5

1 reference

Europe PubMed Central

11 September 2017

Rose F

6

1 reference

Europe PubMed Central

11 September 2017

Grimminger F

7

1 reference

Europe PubMed Central

11 September 2017

Walmrath D

9

1 reference

Europe PubMed Central

11 September 2017

Ghofrani HA

10

1 reference

Europe PubMed Central

11 September 2017

language of work or name

0 references

publication date

1 November 2001

1 reference

Europe PubMed Central

11 September 2017

American Journal of Respiratory and Critical Care Medicine

1 reference

Europe PubMed Central

11 September 2017

164

1 reference

Europe PubMed Central

11 September 2017

9

1 reference

Europe PubMed Central

11 September 2017

1694-1700

1 reference

Europe PubMed Central

11 September 2017

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Aerosolised prostacyclin in adult respiratory distress syndrome.

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. Impact on gas exchange

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Selective pulmonary vasodilation induced by aerosolized zaprinast.

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Inhibition of endogenous nitric oxide synthesis potentiates the effects of sodium nitroprusside but not of adenosine in experimental pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome.

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Phosphodiesterase inhibitors: new opportunities for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.9.2105060

21 January 2018

Identifiers

10.1164/AJRCCM.164.9.2105060

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39412753&oldid=1826492876"